EPISODE · Mar 25, 2026 · 9 MIN
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly
What this episode covers
ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly
NOW PLAYING
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m